Samplix secures €25M to scale microfluidics platform
The Danish biotech secured €25 million in a first close led by WLanholding GmbH to advance its cell analysis platform.
Image: Samplix
Birkerød-based Samplix closed a €25 million (about $27.9 million) first tranche of a funding round with a total goal of €30 million, according to an announcement published by EU-Startups [1]. The financing package includes €3 million in new equity alongside €22 million issued as shareholder convertible bonds [1]. WLanholding GmbH led the transaction [1].
Founded in 2013 and led by chief executive officer Henrik Pfundheller, Samplix builds droplet microfluidics technology engineered for functional single-cell workflows [1]. The company indicated that the capital will bolster its balance sheet while expanding commercial deployment of its Xdrop system, with a specific emphasis on antibody discovery applications [1].
In connection with the investment, Dr. Werner Lanthaler is slated to join the company's board of directors over the coming year [1].
Questions and answers
What is Samplix's core product?
Samplix develops droplet microfluidics systems for functional single-cell analysis, including its proprietary Xdrop platform.
Who led the financing tranche?
The financing was led by WLanholding GmbH.
How is the capital structured?
The €25 million first close consists of €3 million in fresh capital and €22 million in shareholder convertible notes.
Companies & investors in this story
Sources
- 1.Danish BioTech Samplix secures €25 million in first close of financing round to scale antibody discovery — EU-Startups, Oct 28, 2026